- Home
- V vs PFE Comparison
V vs PFE Comparison
Compare V & PFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | V | PFE |
|---|---|---|
| Founded | 1958 | 1849 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 676.2B | 141.6B |
| IPO Year | 2008 | N/A |
Fundamental Metrics
Financial Performance| Metric | V | PFE |
|---|---|---|
| Price | $328.87 | $25.70 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 25 | 11 |
| Target Price | ★ $398.88 | $27.18 |
| AVG Volume (30 Days) | 7.1M | ★ 43.6M |
| Earning Date | 01-29-2026 | 02-03-2026 |
| Dividend Yield | 0.82% | ★ 6.71% |
| EPS Growth | 4.85 | ★ 131.89 |
| EPS | ★ 10.20 | 1.73 |
| Revenue | $40,000,000,000.00 | ★ $62,785,000,000.00 |
| Revenue This Year | $13.38 | N/A |
| Revenue Next Year | $10.19 | N/A |
| P/E Ratio | $32.18 | ★ $14.91 |
| Revenue Growth | ★ 11.34 | 3.89 |
| 52 Week Low | $299.00 | $20.92 |
| 52 Week High | $375.51 | $27.69 |
Technical Indicators
Market Signals| Indicator | V | PFE |
|---|---|---|
| Relative Strength Index (RSI) | 35.23 | 55.61 |
| Support Level | $323.83 | $24.97 |
| Resistance Level | $331.69 | $25.77 |
| Average True Range (ATR) | 6.45 | 0.44 |
| MACD | -3.54 | 0.06 |
| Stochastic Oscillator | 14.46 | 71.91 |
Price Performance
Historical ComparisonAbout V Visa Inc.
Visa is the largest payment processor in the world. In fiscal 2025, it processed almost $17 trillion in total volume. Visa operates in over 200 countries and processes transactions in over 160 currencies. Its systems are capable of processing over 65,000 transactions per second.
About PFE Pfizer Inc.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.